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Abstract
Objective. To quantify the extent to which co-morbid FM is associated with higher disease activity, worse quality of life
(QoL) and poorer response to TNF inhibitors (TNFis) in patients with axial SpA.
Methods. A prospective study recruiting across 83 centres in the UK. Clinical information and patient-reported meas-
ures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting
the FM criteria on disease activity, QoL and response to TNFis.
Results. A total of 1757 participants were eligible for analyses, of whom 22.1% met criteria for FM. Those with co-
morbid FM criteria had higher disease activity [BASDAI average difference FM+  FM 1.04 (95% CI 0.75, 1.33)] and
worse QoL [Ankylosing Spondylitis Quality of Life score difference 1.42 (95% CI 0.88, 1.96)] after adjusting for demo-
graphic, clinical and lifestyle factors. Among 291 participants who commenced biologic therapy, BASDAI scores in those
with co-morbid FM were 2.0 higher at baseline but decreased to 1.1 higher at 12 months. There was no significant
difference in the likelihood of meeting Assessment of SpondyloArthritis international Society 20 criteria at 12 months.
Less improvement in disease activity and QoL over 3 months of TNFi therapy was most strongly related to high scores on
the FM criteria symptom severity scale component.
Conclusion. Fulfilling criteria for FM has a modest impact on the assessment of axial SpA disease activity and QoL and
does not significantly influence response to biologic therapy. Those with a high symptom severity scale on FM assess-
ment may benefit from additional specific management for FM.
Key words: axial spondyloarthritis, biologic therapy, cohort study, co-morbidity, disease activity, disease regis-
ter, epidemiology, fibromyalgia, outcome, response
Rheumatology key messages
. One in five patients recruited to the BSR register for patients with axial SpA meet research criteria for FM.
. Axial SpA patients with co-morbid FM were equally likely to meet response criteria at 12 months.
. Higher scores on the FM criteria symptom severity scale predicted less benefit from TNF inhibitors.
Introduction
The issue of FM as a co-morbidity to axial SpA (axSpA) is
of considerable recent interest. In July 2013, the US Food
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and Drug Administration (FDA) met to consider TNF inhibi-
tors (TNFis) in patients with non-radiographic axSpA
based on the Assessment of SpondyloArthritis interna-
tional Society (ASAS) classification criteria [1]. The FDA
Arthritis Advisory Committee recognized the unmet need
for effective pharmacologic therapy for patients who had
positive MRI rather than radiographic changes, or based
on positive HLA-B27 plus other characteristic SpA fea-
tures, but who did not fulfil the modified New York
(mNY) criteria for AS [2]. However, they were concerned
about the specificity of the ASAS criteria [3] and the pos-
sibility that patients with highly prevalent conditions such
as mechanical back pain or FM might be incorrectly diag-
nosed with non-radiographic axSpA and be inappropri-
ately treated with TNFi medications. This highlights the
need to better understand the characteristics of axSpA
patients who have co-morbid FM in order to assess and
distinguish the two conditions (including when they
coexist) and to develop treatment strategies that can ef-
fectively work in parallel.
This led to research that sought to understand how
often axSpA and FM co-occur. Notwithstanding the fact
that research criteria for FM have not been validated in the
context of inflammatory rheumatic conditions, studies
have sought to understand how often people with
axSpA met one or more of the criteria for FM. These
demonstrated that co-occurrence was common. We
have shown that 21% of 1504 persons within the British
Society for Rheumatology Biologics Register of AS
(BSRBR-AS) met 2011 criteria for FM (also known as the
modified 2010 criteria and as research criteria) [4]. In a
smaller study of 200 patients meeting ASAS criteria for
axSpA, Baraliakos et al. [5] found that 24% met the
above research criteria while 14% met the previous
1990 ACR criteria. This is consistent with the observation
of high prevalence of FM in inflammatory rheumatic dis-
eases generally [6]. However, identifying co-morbid FM in
people with axSpA is challenging. The ACR 1990 criteria
for FM require the report of axial skeleton pain, which is
one of the key clinical features of axSpA. These criteria, as
well as the 2011 criteria, require multisite pain, which is
also reported by axSpA patients due to inflammatory
enthesitis/synovitis [7, 8].
The key issue is distinguishing and providing appropri-
ate management for both conditions when they occur to-
gether. A pooled analysis of data from clinical trials
treating axSpA patients with etanercept, SSZ or placebo
showed a higher disease burden and poorer response to
treatment in women and identified the possibility that this
may be due to concomitant FM [9, 10]. We currently do
not know how patients with co-morbid FM respond to
TNFi therapy compared with those without. However, sev-
eral standard disease indices, including the BASDAI, as
well as wider measures of disease impact [such as the
Ankylosing Spondylitis Quality of Life (ASQoL) index] are
based entirely on patient reports and may be inflated
due to co-morbid FM. This could lead to inappropriate
management since guidelines include BASDAI score as
one determinant for use of TNFi therapy [1113].
The purpose of this analysis is therefore 2-fold: to quan-
tify the extent to which meeting criteria for FM is asso-
ciated with higher measures of disease activity and
impact (aim 1) and to determine whether meeting research
criteria for FM is associated with poorer response on first
use of TNFi therapy (aim 2).
Methods
The BSRBR-AS is a prospective cohort study that has
recruited patients from 83 secondary care centres in the
UK who have a physician diagnosis of axSpA and meet
the ASAS defined criteria. Recruitment started in
December 2012, initially for people meeting the ASAS
imaging criteria for axSpA. Patients meeting only ASAS
clinical criteria were subsequently eligible to be recruited
in November 2014. All participants are naı¨ve to TNFi ther-
apy at the time of recruitment but may either be starting
such therapy or continuing on current non-TNFi therapy.
The study protocol has previously been published [14]
but, in brief, participants starting TNFi therapy have clin-
ical and patient-reported information collected at the start
of therapy and 3, 6 and 12 months later. Those not on
TNFi therapy have information collected at recruitment
and annually thereafter but may transfer to the follow-up
schedule of participants on TNFi therapy if they com-
menced such therapy during the course of the study.
Eligible TNFi therapies were adalimumab, etanercept
and certolizumab pegol. From September 2015, the pa-
tient-reported data included the 2011 FM criteria.
Data collected from or measured on each participant at
recruitment and each follow-up point included cigarette
smoking (current, ex-smoker, never smoker); the
BASDAI, BASFI and BASMI [1517]; the 18-item ASQoL
scale, providing a score from 0 [good quality of life (QoL)]
to 18 (poor QoL) [18] and the Hospital Anxiety and
Depression Scale (HADS), a measure of emotional dis-
tress, anxiety disorders and depression. There are two
subscales, for anxiety and depression, each with scores
ranging from 0 to 21, with higher scores indicating more
severe problems [19].
Information was collected in relation to the 2011 FM
criteria [8]. There are two components to the criteria: the
Widespread Pain Index (WPI) and the Symptom Severity
Scale (SSS). The WPI records in how many of 19 body
areas the respondent reports pain in the past week (score
019). For the SSS, respondents indicate the severity of
fatigue, waking unrefreshed and cognitive symptoms such
as brain fog over the past week (scored 03 each). The
criteria also include three items on whether depression,
headaches and pain or cramps in the lower abdomen
have occurred in the past 6 months (score 1 each if pre-
sent), giving a maximum total score of 12.
CRP was measured at recruitment but was only mea-
sured subsequently if clinically indicated. A measure of
socio-economic status, the Index of Multiple Deprivation
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(IMD), was derived from the postcode of the residence of
participants and categorized into quintiles with references
to their country of residence [20, 21].
Ethical approval was obtained from the National
Research Ethics Service Committee North East—County
Durham and Tees Valley (reference 11/NE/0374) and in-
formed consent was obtained from all participants.
Analysis
Aim 1
Participants were included if they had completed the FM
criteria either at recruitment or follow-up. Data from the
first completion of the items that contribute to this criteria
were used (and are referred to as baseline). The effect of
FM status on baseline BASDAI and ASQoL was
determined. Thereafter, multivariate linear regression ana-
lyses were used to evaluate the influence of FM status on
baseline disease activity (BASDAI) adjusted for BASMI
and CRP (both measured within 3 months of the self-
report data), BASFI, age group, gender, IMD, disease
management (on a TNFi) and smoking status and baseline
ASQoL adjusted for BASDAI, BASFI, BASMI, age group,
gender, IMD, disease management and smoking status.
As the availability of CRP restricted the numbers available
for analysis, and it was shown not to be related to
BASDAI, it was only included in an additional (sensitivity
analysis) model predicting ASQoL. Both the BASDAI and
ASQoL analyses were first conducted with a dichotomous
FM status variable and then using the WPI and SSS com-
ponents of the criteria instead.
Aim 2
Participants were included in this analysis if they had
completed FM research criteria within the 6 months be-
fore or 1 month after commencing TNFi therapy for the
first time. They were also required to have completed at
least one follow-up questionnaire 3, 6 or 12 months later.
Two-sample t-tests were used to compare differences in
BASDAI and ASQoL between patients meeting FM cri-
teria (called FM+) and those who did not (FM) at base-
line and 3, 6 and 12 months, as well as ASAS20 and
ASAS40 responses at each of these follow-up points.
In predicting the contribution of FM status on the
change in BASDAI after 3 months, adjustment was
made for baseline BASDAI, BASFI, age group, IMD,
gender and smoking status, while in the analysis predict-
ing ASQoL change after 3 months, adjustment was made
additionally for baseline ASQoL. Analysis was again con-
ducted first with dichotomous FM criteria status and
then with the WPI and SSS components of the criteria.
Inclusion of clinically measured variables reduced the
sample size available to the analysis, but a sensitivity
analysis with CRP and BASMI was included to investi-
gate their effects. We separately included baseline
HADS to determine whether this mediated the relation-
ship between FM status and treatment response.
All analyses were conducted using Stata 14 SE 64-bit
(StataCorp, College Station, TX, USA) for statistical ana-
lysis and the June 2017 study dataset.
Results
A total of 1757 participants (67% male) completed the
research criteria for FM on at least one occasion and
were eligible for the current analyses. Their median age
was 50.8 years, with a median time since symptom onset
of 27 years, and 80.2% of those who had been tested
were HLA-B27 positive. Most participants (66.8%) met
the mNY criteria for AS, an additional 28.4% fulfilled
ASAS imaging criteria but not mNY and 4.8% fulfilled
only ASAS clinical criteria for axSpA.
Influence of FM status on disease activity and
QoL (aim 1)
Those who were FM+ at baseline [n= 388 (22.1%)] had
higher BASDAI scores than those who were FM [6.7 vs
3.6; difference 3.1 (95% CI 2.8, 3.3)]. A higher BASDAI
score was independently predicted by being FM+ (1.04
higher average scores) in a multivariable linear regression
model (which included participants who had a CRP within
3 months of the self-reported information; n= 1093)
(Table 1). Additional predictors were higher BASFI (0.67
average increase in BASDAI per unit increase in BASFI),
lower BASMI (0.14/U), younger age group and not being
on a TNFi (0.34 higher average score). BASDAI was not
significantly related to CRP, gender, smoking or IMD.
When the individual component scores of the FM criteria
were entered in the model (instead of the dichotomous FM
variable), BASDAI was related to both the WPI score (0.11
average increase in BASDAI for every additional area of
pain reported) and the SSS (0.20 average increase/unit).
Those who were FM+ at baseline had poorer QoL
scores than those who were FM [13.1 vs 6.1; difference
7.0 (95% CI 6.5, 7.6)]. Poorer QoL at baseline was pre-
dicted, on multivariable analysis, by being FM+ (1.42
higher average ASQoL) in addition to higher BASDAI
score (0.85 increase in ASQoL per unit increase in
BASDAI), higher BASFI (1.00/U), lower BASMI (0.13/U),
female gender (0.74 higher average ASQoL score) and
being a current smoker (0.94 higher average score)
(Table 2). QoL increased with older age group but was
not related to TNFi management or IMD. When the FM
component scores were entered, poorer QoL was
strongly related to SSS (0.50 increase in ASQoL/unit),
with a 0.09 in increase in ASQoL per unit increase in
WPI. As a sensitivity analysis, when the CRP was included
in model 2 it was not related to QoL [coefficient 0.00 (95%
CI 0.02, 0.02)].
Response to TNFi therapy according to FM
status (aim 2)
There were a total of 291 participants who commenced
TNFi therapy and had completed FM criteria within the
required timescale. Of these, 139, 123 and 74 had
reached the follow-up and completed a questionnaire 3,
6 and 12 months later, respectively. At the time of com-
mencing TNFi therapy, participants who were FM+ had
significantly higher BASDAI scores [7.2 vs 5.2; difference
2.0 (95% CI 1.5, 2.4)]. They continued to have higher
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scores throughout the follow-up, although the magnitude
of the difference decreased over time: 3 months [5.7 vs
3.7; difference 1.9 (95% CI 1.0, 2.8)], 6 months [4.8 vs
3.2; difference 1.6 (95% CI 0.7, 2.6)] and 12 months [4.1
vs 3.1; difference 1.1 (95% CI 0.0, 2.2)]. QoL was poorer
among those who were FM+ [14.0 vs 9.4; difference 4.6
(95% CI 3.5, 5.7)] and remained so at 3 months [10.5 vs
7.0; difference 3.5 (95% CI 1.5, 5.5)], 6 months [10.2
vs 5.6; difference 4.6 (95% CI 2.5, 6.6)] and 12 months
[9.0 vs 5.4; difference 3.6 (95% CI 0.9, 6.3)] (Fig. 1). It is
notable in FM+ patients that BASDAI continues to de-
crease throughout the 12 month follow-up period.
Throughout the follow-up, those originally FM+ were less
likely to meet ASAS20 response criteria at all time points.
The differences decreased throughout the follow-up and
none were statistically significant: 3 months [36% vs 46%;
difference 10% (95% CI 28, 8)], 6 months [56 vs 61%;
difference 5% (95% CI 24, 14)] and 12 months [60 vs
63%; difference 4% (95% CI 30, 23)]. Similar-size dif-
ferences in response were observed for ASAS40:
3 months [24 vs 34%; difference 11% (95% CI 28,
7)], 6 months [39 vs 44%; difference 5% (95% CI 24,
14)] and 12 months [32 vs 42%; difference 11% (95% CI
37, 16)]. The proportion of participants who were FM+ at
baseline and who continued to meet the criteria at follow-
up was 36.2% at 3 months, 40.5% at 6 months and 40%
at 12 months. The decrease in the proportion of patients
fulfilling the FM criteria over time was due to improve-
ments in both WPI and SSS. WPI improved by 1.5, 1.8
and 1.4 over 3, 6 and 12 months, respectively, and SSS
improved by 0.8, 1.2 and 0.8, respectively. These repre-
sent very similar improvements as a percentage of the
relevant maximum scale score (e.g. 8 and 7% at 3 months
for WPI and SSS, respectively).
A multivariable model predicting the change in BASDAI
(BASDAIbaseline  BASDAI3 months) demonstrated that those
who were FM+ at baseline had 0.58 less improvement in
BASDAI than those who were FM, but this was not stat-
istically significant (Table 3). Larger improvements were
related to higher baseline BASDAI (every unit increase in
BASDAI associated with an average 0.72 greater improve-
ment in BASDAI) and lower baseline BASFI (0.38 less im-
provement/unit increase). However, when the effect of the
individual components of FM criteria were considered,
higher scores on the SSS were significantly associated
with a poorer response (0.32 lower average improvement
TABLE 1 Predictors of the BASDAI score at baseline
Baseline variable
Model 1 (n= 705),
coefficient (95% CI)
Model 2 (n= 626),
coefficient (95% CI)
Constant 2.54 ( 1.97, 3.12) 1.33 (0.73, 1.93)
BASMI 0.14 (0.22, 0.07) 0.08 (0.15, 0.00)
BASFI 0.67 (0.62, 0.73) 0.51 (0.45, 0.57)
CRP, mg/dl 0.00 (0.01, 0.01) 0.00 (0.01, 0.01)
Age, years
<30 0 0
3039 0.26 (0.75, 0.22) 0.16 (0.62, 0.30)
4049 0.41 (0.89, 0.07) 0.15 (0.61, 0.30)
5059 0.50 (0.98, 0.01) 0.28 (0.75, 0.18)
6069 0.86 (1.40, 0.33) 0.47 (0.98, 0.04)
570 1.03 (1.62, 0.45) 0.58 (1.15, 0.00)
Gender
Male 0 0
Female 0.20 (0.04, 0.43) 0.06 (0.17, 0.30)
Deprivation (quintiles)
1 (highest deprivation) 0 0
2 0.16 (0.57, 0.24) 0.12 (0.51, 0.28)
3 0.33 (0.73, 0.06) 0.31 (0.70, 0.09)
4 0.11 (0.49, 0.27) 0.10 (0.48, 0.28)
5 0.33 (0.73, 0.06) 0.25 (0.64, 0.15)
Management
Biologic 0.34 (0.58, 0.09) (0.53, 0.06)
Smoking status
Never 0 0
Ex 0.04 (0.21, 0.28) 0.01 (0.24, 0.23)
Current 0.01 (0.31, 0.33) 0.01 (0.32, 0.31)
FM 1.04 ( 0.75, 1.33) Not entered
FM Not entered
WPI 0.11 (0.08, 0.15)
SSS 0.20 (0.15, 0.25)
Model 1 fit: R2 = 0.6454; model 2 fit: R2 = 0.7055.
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per unit increase in the SSS). When CRP or BASMI was
added to model 2 (as a sensitivity analysis, since their
inclusion restricted numbers available for analysis), they
were not associated with an improvement in BASDAI [0.00
(95% CI 0.02, 0.03) and 0.21 (95% CI 0.06, 0.48), re-
spectively] and neither was HADS (anxiety) [severe anxiety
0.18 (95% CI 1.36, 1.72) per unit increase in score] or
HADS (depression) [severe depression 0.51 (95% CI
2.45, 1.42) per unit increase in score] when put into
the model together.
A corresponding analysis was run with QoL as the out-
come (ASQoLbaseline  ASQoL3 months). High scores on the
SSS for the FM criteria were predictive of lower improve-
ment in QoL, as were poorer QoL and worse disease ac-
tivity on commencing treatment (Table 4). When CRP or
BASMI was added to model 2 (again as a sensitivity ana-
lysis), they were not associated with improvement in
ASQoL [0.11 (95% CI 0.47, 0.69) and 0.01 (95% CI
0.07, 0.06), respectively] and neither was HADS (anxiety)
[severe anxiety 0.79 (95% CI 4.13, 2.55)] or HADS (de-
pression) [severe depression 3.29 (95% CI 7.48, 0.91)].
Discussion
Patients with axSpA who were FM+ had only modestly
higher disease activity and worse QoL, after adjustment
for disease indices, demographic and socio-economic
factors. Poor QoL was more strongly determined by a
high score on the SSS of FM criteria, indicating a high
burden of somatic symptoms. Persons who were FM+
FIG. 1 Disease activity and QoL after commencement of
biologic therapy
TABLE 2 Predictors of the ASQoL score at baseline
Baseline variable
Model 1 (n= 886),
coefficient (95% CI)
Model 2 (n= 796),
coefficient (95% CI)
Constant 0.88 (0.17, 1.93) 0.88 (1.94, 0.18)
BASDAI 0.85 ( 0.72, 0.99) 0.54 ( 0.39, 0.68)
BASFI 1.00 ( 0.87, 1.13) 0.91 ( 0.78, 1.04)
BASMI 0.13 (0.26, 0.00) 0.10 (0.23, 0.03)
Age (years)
<30 0 0
3039 0.34 (1.18, 0.50) 0.05 (0.85, 0.76)
4049 1.10 (1.93, 0.28) 0.64 (1.43, 0.15)
5059 1.55 (2.40, 0.71) 1.07 (1.88, 0.25)
6069 1.71 (2.63, 0.79) 0.76 (1.66, 0.13)
570 2.20 (3.21, 1.19) 1.31 (2.31, 0.31)
Gender
Male 0 0
Female 0.74 (0.33, 1.16) 0.58 ( 0.16, 0.99)
Index of Multiple Deprivation (quintiles)
1 (highest deprivation) 0 0
2 0.14 (0.85, 0.57) 0.03 (0.68, 0.74)
3 0.14 (0.84, 0.55) 0.11 (0.60, 0.82)
4 0.24 (0.90, 0.42) 0.09 (0.76, 0.58)
5 0.34 (1.02, 0.34) 0.15 (0.84, 0.55)
Management
Biologic therapy 0.11 (0.33, 0.56) 0.01 (0.45, 0.43)
Smoking status
Never 0 0
Ex-smoker 0.05 (0.37, 0.47) 0.05 (0.36, 0.46)
Current 0.94 ( 0.38, 1.49) 0.97 ( 0.42, 1.52)
FM 1.42 ( 0.88, 1.96) Not entered
FM Not entered
WPI 0.09 (0.02, 0.16)
SSS 0.50 (0.41, 0.59)
Model 1 fit: R2 = 0.7467; model 2 fit: R2 = 0.7821.
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had higher BASDAI scores on commencement of TNFi
therapy and throughout the 12 month follow-up, although
the difference in magnitude decreased over the period of
treatment. There was no significant difference in the like-
lihood of meeting ASAS20 or ASAS40 response criteria
according to FM status. While FM status was not signifi-
cantly related to response to therapy, as assessed by
BASDAI or ASQoL, high somatic symptom burden was
associated with worse response. Approximately two in
five persons who met FM criteria at commencement of
therapy continued to do so at each follow-up over the
year.
The BSRBR-AS is a national register involving non-spe-
cialist and specialist centres and thus the patients re-
cruited are likely to represent the spectrum encountered
in routine clinical practice. The study protocol dictated
that participants were followed up clinically and by ques-
tionnaire at 3, 6 and 12 months. This schedule was chosen
to fit in with routine clinical practice. If the routine follow-
up did not occur (or sufficient time had not passed for the
follow-up to be due) or the participant did not return the
questionnaire, then they could not fully participate in all
the analyses presented. Therefore, for the 12 month
follow-up in particular, the numbers analysed are consid-
erably lower than those recruited. However, it should be
noted that the patterns of response are very similar
across the follow-up and therefore this is unlikely to
have impacted the interpretation of results. Specifically,
we examined whether BASDAI or ASQoL were importantly
or statistically significantly related to the likelihood of
follow-up and confirmed they were not. Similarly, we
opted not to use the ASDAS as an outcome measure be-
cause of the necessity that the clinic visit (for the CRP) and
the questionnaire (for self-reported measures) occur suf-
ficiently close in time. CRP was shown not to be related to
BASDAI (at baseline) or as a predictor of response to ther-
apy and did not play an important part in the analyses.
While the patient-reported measures could be performed
without a clinic visit, the BASMI required that a clinical visit
had occurred. However, the BASMI was shown not to be
importantly related to disease activity or a predictor of
response.
In interpreting the results of this study it is important to
consider that although we were able to determine whether
participants met research criteria, this is not the same as a
clinical diagnosis of FM. Distinguishing, for example, mul-
tisite pain of axSpA from the axial and widespread pain of
FM is extremely challenging. As previously noted, the cri-
teria for FM have not been validated in people with inflam-
matory arthritis and indeed the 2010 [22] and 2011
research criteria [8] (but not the most recent 2016 criteria
[23]) have sought to exclude persons from meeting FM
criteria if they have symptoms that could be explained
by inflammatory conditions.
TABLE 3 Predicting response to biologic therapy: improvements in the BASDAI
Baseline variable
Model 1 (n= 135),
coefficient (95% CI)
Model 2 (n= 121),
coefficient (95% CI)
Constant 0.99 (2.72, 0.75) 0.28 (2.03, 1.48)
BASDAI 0.72 (0.49, 0.95) 0.84 (0.60, 1.08)
BASFI 0.38 (0.60, 0.17) 0.17 (0.41, 0.07)
Age (years)
<30 0 0
3039 0.75 (0.56, 2.07) 0.82 (0.46, 2.10)
4049 0.58 (0.73, 1.89) 0.29 (0.98, 1.56)
5059 0.31 (1.11, 1.73) 0.26 (1.14, 1.66)
6069 0.41 (1.03, 1.86) 0.13 (1.35, 1.62)
570 1.03 (3.25, 1.19) 0.89 (3.22, 1.43)
Index of Multiple Deprivation (quintiles)
1 (highest deprivation) 0 0
2 0.58 (0.71, 1.87) 0.66 (0.68, 2.00)
3 0.20 (1.43, 1.03) 0.50 (1.79, 0.80)
4 0.91 (0.28, 2.11) 0.71 (0.52, 1.94)
5 0.55 (0.67, 1.78) 0.19 (1.12, 1.49)
Gender
Male 0 0
Female 0.61 (1.38, 0.17) 0.10 (0.91, 0.70)
Smoking status
Never 0 0
Ex-smoker 0.13 (0.72, 0.98) 0.21 (0.64, 1.06)
Current 0.19 (0.76, 1.13) 0.59 (0.40, 1.57)
FM criteria met 0.58 (1.40, 0.23) Not applicable
FM Not applicable
WPI 0.10 (0.24, 0.03)
SSS 0.32 (0.53, 0.12)
Model 1 fit: R2 = 0.3261; model 2 fit: R2 = 0.4079.
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This is one of the first studies to examine these issues in
relation to co-morbid FM in people with axSpA. We and
others have previously reported that disease indices are
substantially elevated in patients who meet FM criteria [4,
24]. This study provides new information that when the
comparison of FM+ and FM patients takes account of
clinical, demographic and lifestyle differences between
the groups, the effect on disease indices is much less
pronounced. Using the FM rapid screening tool, (FIRST)
Bello et al. [24] found that those who scored high on the
tool were more likely to discontinue TNFi therapy and that
this was a predictor of discontinuation of first therapy (to-
gether with peripheral involvement) on multivariable ana-
lysis. Molto et al. [25] found that response to therapy was
lower in those who scored high on the FIRST for most
endpoints, but not CRP. This study confirms this but has
looked at a longer-term outcome (12 months vs 3 months)
and, using internationally accepted criteria, has identified
one specific FM component (SSS), rather than meeting
FM criteria generally, that identifies persons most likely
to have a poor response.
The clinical implications from this study are that since
meeting criteria for FM per se only had a modest effect on
BASDAI (i.e. 1 point) or ASQoL (1.5 points), there should
not be undue concern that FM distorts disease indices.
Being FM+ also did not predict poor or non-response to
TNFi therapy among axSpA patients. Indeed, with TNFi
therapy and a reduction in BASDAI, three of five people
with co-morbid FM will no longer meet the criteria for FM.
Specifically, the widespread distribution of pain was not a
key determinant of response, but instead it was the high
somatic symptom burden captured by the SSS of the FM
criteria that was a strong predictor. As an example,
assuming a patient had an SSS of 12 and a WPI of 2,
then the predicted improvement on BASDAI would be 4
less than a patient scoring zero on both scales, whereas a
patient with an SSS of 2 and WPI of 14 would have an
improvement only 2 less than a patient scoring zero on
both scales. Specifically we did not find that mood was an
independent predictor of response. For patients with a
high SSS, treatments employing a cognitive behaviour ap-
proach, which have been shown to be effective for FM [26]
may be indicated, and studies to test the feasibility of
such an approach are under way.
In summary, meeting the criteria for FM in this study had
only a modest impact on the assessment of disease ac-
tivity by the BASDAI and did not influence the response to
TNFi therapy. A high score on the SSS, representing a
high somatic symptom burden, was a greater influence
on QoL, assessed by ASQoL and identified persons who
had significantly poorer response to TNFi therapy. It may
be useful for rheumatologists to identify patients with a
TABLE 4 Predicting response to biologic therapy: improvements in QoL (ASQoL score)
Variable
Model 1 (n= 133),
coefficient (95% CI)
Model 2 (n= 119),
coefficient (95% CI)
Constant 0.93 (4.72, 2.86) 0.15 (3.96, 3.66)
ASQOL 0.30 (0.01, 0.59) 0.52 (0.20, 0.84)
BASDAI 0.36 (0.17, 0.89) 0.52 (0.03, 1.06)
BASFI 0.50 (1.06, 0.06) 0.23 (0.82, 0.35)
Age (years)
3039 2.37 (0.46, 5.21) 2.31 (0.46, 5.08)
049 2.16 (0.71, 5.03) 1.75 (1.03, 4.53)
5059 0.93 (2.20, 4.07) 1.01 (2.07, 4.09)
6069 0.90 (2.30, 4.10) 0.49 (2.74, 3.72)
570 0.82 (3.99, 5.62) 1.60 (3.42, 6.63)
Index of Multiple Deprivation (quintiles)
1 (highest deprivation) 0 0
2 1.27 (4.05, 1.51) 0.45 (3.35, 2.46)
3 1.28 (3.97, 1.42) 1.01 (3.85, 1.83)
4 0.77 (1.80, 3.35) 0.95 (1.71, 3.61)
5 0.40 (3.04, 2.24) 0.61 (3.42, 2.20)
Gender
Female 0.67 (2.37, 1.04) 0.17 (1.60, 1.94)
Smoking status
Never 0 0
Ex-smoker 1.31 (0.55, 3.17) 1.33 (0.51, 3.18)
Current 0.43 (1.72, 2.57) 0.72 (1.48, 2.92)
FM criteria met 0.51 (2.29, 1.26) Not applicable
FM Not applicable
WPI 0.19 (0.49, 0.10)
SSS 0.74 (1.22, 0.25)
Model 1 fit: R2 = 0.1830; model 2 fit: R2 = 0.2896.
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high SSS who are commencing TNFi therapy and to con-
sider additional non-pharmacological therapies to target
such symptoms and potentially improve outcome.
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